Eight More Years: US Supreme Court Sinks Sandoz’ Hopes On Enbrel
Erelzi Biosimilar Etanercept Is Now Barred Until 2029 In The US
Sandoz’ arguments urging the US Supreme Court to review patent litigation around Amgen’s Enbrel have fallen on deaf ears, blocking a route to market for biosimilar etanercept until 2029 in the US.
